[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555395":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":7,"responsibleParty":18,"collaborators":7,"id":22,"slug":23,"hasResults":24,"nctId":25,"briefTitle":26,"officialTitle":27,"acronym":7,"eligibilityCriteria":28,"healthyVolunteers":24,"sex":29,"minAge":30,"maxAge":31,"enrollmentInfo":32,"targetDuration":7,"studyType":35,"phases":7,"briefSummary":36,"conditions":37,"keywords":7,"overallStatus":39,"whyStopped":7,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":7},{"fullName":5,"class":6},"Central South University","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Qin Lixia, Principal Investigator","CONTACT","+86 18207406524","qinlixia1027@csu.edu.cn",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"Gui Meilin, student","+86 15286516701","guimeilin2021@163.com",{"type":19,"investigatorFullName":20,"investigatorTitle":21,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Lixia Qin","Principal Investigator","100555395","exploring-sarcopenia-in-parkinsons-disease-patients-by-combining-serum-biomarker-levels-100555395",false,"NCT06511531","Exploring Sarcopenia in Parkinson's Disease Patients by Combining Serum Biomarker Levels","Clinical Features and Possible Mechanisms in Patients With Sarcopenia in Parkinson's Disease","Inclusion Criteria:\n\nDiagnosed as either ''definite'' or ''probable'' PD based on Chinese diagnostic criteria of Parkinson\\'s disease (2016 version)\n\nExclusion Criteria:\n\nParkinson\\'s syndrome or Parkinsonian superimposed syndrome due to encephalitis, cerebrovascular disease, poisoning, trauma, drugs or other factors","ALL","30 Years","80 Years",{"count":33,"type":34},200,"ESTIMATED","OBSERVATIONAL","Parkinson\\'s Disease (PD) and sarcopenia are prevalent age-related syndromes, often occurring simultaneously within individuals. Sarcopenia is notably common among PD patients, with severe cases affecting approximately one in every five individuals with PD. Moreover, sarcopenia is closely linked to the accelerated progression of PD, diminished quality of life, heightened mortality risk, and increased susceptibility to falls and fractures. Therefore, early detection of sarcopenia assumes particular significance as it offers an opportunity for interventions aimed at mitigating or delaying muscle degeneration, potentially influencing PD outcomes. This review will delve into the relationship between sarcopenia and PD, methods for screening and testing sarcopenia, and potential avenues for further research and the development of strategies for risk reduction and treatment",[38],"Parkinson Disease","NOT_YET_RECRUITING","2024-07-15",{"date":42,"type":43},"2024-07-22","ACTUAL",{"date":45,"type":34},"2024-08-01",{"date":47,"type":34},"2024-09-01",{"name":5,"class":6}]